Stock Research: Sino Biopharmaceutical

Independent stock analysis through peer comparison: Get the 360° View as an objective basis for stock decision-making and explore the detailed ranks.

Sino Biopharmaceutical

HKG:1177 KYG8167W1380
40
  • Value
    53
  • Growth
    89
  • Safety
    Safety
    20
  • Combined
    58
  • Sentiment
    36
  • 360° View
    360° View
    40
Unlock
What factors are driving this 360° View?
Subscribe to View
Company Description

ANALYSIS: With an Obermatt 360° View of 40 (better than 40% compared with alternatives), overall professional sentiment and financial characteristics for the stock Sino Biopharmaceutical are below the industry average. The 360° View is based on consolidating four consolidated indicators, with half of the metrics below and half above average for Sino Biopharmaceutical. The consolidated Value Rank has an attractive rank of 53, which means that the share price of Sino Biopharmaceutical is on the lower side compared with the typical size in indicators such as revenues, profits, and invested capital. This means the stock price is lower than for 53% of alternative stocks in the same industry. The consolidated Growth Rank has a good rank of 89, which means that the company experiences above-average growth momentum when looking at financial metrics such as revenue, profit, and invested capital growth as well as stock returns. But the professional market sentiment is below average compared with other stock investment alternatives with a Sentiment Rank of 36. Professional investors are more confident in 64% other stocks. Worryingly, the company has risky financing, with a Safety rank of 20. This means 80% of comparable companies have a safer financing structure than Sino Biopharmaceutical. ...read more

more
Index
Hang Seng
Similar Add to Watchlist Similar See Similar Stocks
The higher the 360° View, the better the stock performed against its peers, considering all metrics. The 360° View represents an average of the other 5 ranks and is then scaled to a rank from 1 to 100. The shaded values are illustrative only.
Last update: 23-Apr-2026.

Make Sense of the Ranks

The higher, the better. For every stock, we judge its performance against its peers and rank it on a scale of 1 to 100. These ranks are percentiles: a rank of 75 means the company outperforms 75% of its peers in that specific area. The higher the rank, the better the stock stacks up against its peers.

Detailed and Historical Ranks

Deep dive into 15 detailed ranks and 3 years of history. Unlock the analysis.

Unlock Ranks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2025 2024 2023
Value
53 n/a n/a n/a
Growth
89 n/a n/a n/a
Safety
Safety
20 n/a n/a n/a
Sentiment
36 n/a n/a n/a
360° View
360° View
40 n/a n/a n/a
Unlock Similar Stocks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2025 2024 2023
Analyst Opinions
71 n/a n/a n/a
Opinions Change
31 n/a n/a n/a
Pro Holdings
n/a n/a n/a n/a
Market Pulse
18 n/a n/a n/a
Sentiment
36 n/a n/a n/a
Unlock Similar Stocks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2025 2024 2023
Value
53 n/a n/a n/a
Growth
89 n/a n/a n/a
Safety Safety
20 n/a n/a n/a
Combined
58 n/a n/a n/a
Unlock Similar Stocks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2025 2024 2023
Price vs. Sales (P/S)
48 n/a n/a n/a
Price vs. Earnings (P/E)
39 n/a n/a n/a
Price vs. Book (P/B)
32 n/a n/a n/a
Dividend Yield
83 n/a n/a n/a
Value
53 n/a n/a n/a
Unlock Similar Stocks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2025 2024 2023
Revenue Growth
56 n/a n/a n/a
Profit Growth
78 n/a n/a n/a
Capital Growth
82 n/a n/a n/a
Stock Returns
79 n/a n/a n/a
Growth
89 n/a n/a n/a
Unlock Similar Stocks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2025 2024 2023
Leverage
36 n/a n/a n/a
Refinancing
4 n/a n/a n/a
Liquidity
77 n/a n/a n/a
Safety Safety
20 n/a n/a n/a

Similar Stocks

Discover high‑ranked alternatives to Sino Biopharmaceutical and broaden your portfolio horizons.

Galaxy Entertainment

HKG:27
Country: Hong Kong
Industry: Casinos & Gaming
Size: X-Large
Full Stock Analysis

Shionogi

TYO:4507
Country: Japan
Industry: Pharmaceuticals
Size: X-Large
Full Stock Analysis

CK Asset Holdings

HKG:1113
Country: Hong Kong
Industry: Real Estate Development
Size: X-Large
Full Stock Analysis

Perusahaan Perkebunan London Sumatra Indonesia

JKT:LSIP
Country: Hong Kong
Industry: Agricultural Products
Size: Medium
Full Stock Analysis

Frequently Asked
Questions

This is a high-quality, high-growth stock with positive sentiment. However, the financing is on the riskier side. It is best for a growth-focused investor willing to accept higher financial risk for potentially higher shareholder returns.

Obermatt provides unbiased stock analysis as a completely independent third party. We have no conflicts of interest with individual stock titles. Our data-driven analysis is based on algorithms honed over twelve years, giving you analysis that is free from personal bias and conflicts of interest.

The 360° View Rank indicates a company's overall performance across all major financial and non-financial metrics tracked by Obermatt. A 360° View Rank of 75 means the company is more well-rounded than 75% of similar companies. A high score indicates that the company is strong across the board; it is attractively priced, growing sustainably, financially stable, and well-regarded by the market. Learn more.

Become an Obermatt subscriber and see all of the similar stocks here.

The Obermatt Advantage

Ready to Elevate Your Investing?
Get Started Today

Choose the Obermatt subscription that best fits your needs.


30-day money back guarantee. Your subscription will renew until you cancel it, which you can do at any time.

What Our Customers Say

See how Obermatt improved their investing: